Table 2 |
||||
|
Molecular mass of immunoprecipitated TTR (Da, mean ± SD) assigned to different forms1 of TTR between serum and ascitic fluid of 20 representative women with ovarian cancer. Values in brackets represent mass differences of modified TTR in relationship to the native form of TTR (Da, mean ± SD). |
||||
|
TTR |
cysTTR |
cysglycTTR |
glutTTR |
|
|
|
||||
|
serum |
13757.7 ± 7.1 |
13875.8 ± 12.8 (118.1 ± 13.7) |
13923.6 ± 21.0 (166.8 ± 20.9) |
14062.1 ± 24.7 (306.4 ± 23.9) |
|
ascitic fluid |
13752.7 ± 16.5 |
13876.9 ± 13.3 (124.2 ± 13.7) |
13926.8 ± 11.1 (176.8 ± 1.8) |
14042.5 ± 27.0 (294.6 ± 22.7) |
|
|
||||
|
1 TTR = native TTR; cysTTR = TTR + cysteinylation; cysglycTTR = TTR + cysteinylglycine; glutTTR = TTR + glutathione; no significant differences between molecular masses of serum and ascitic fluid could be observed |
||||
|
Gericke et al. BMC Cancer 2005 5:133 doi:10.1186/1471-2407-5-133 |
||||
